DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide

AIMS: In the initial 26-week, double-blind, double-dummy assessment period of the DURATION-2 trial in patients with Type 2 diabetes on metformin, the once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist exenatide once-weekly resulted in greater HbA(1c) improvement and weight reduction compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Wysham, C, Bergenstal, R, Malloy, J, Yan, P, Walsh, B, Malone, J, Taylor, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123706/
https://www.ncbi.nlm.nih.gov/pubmed/21434995
http://dx.doi.org/10.1111/j.1464-5491.2011.03301.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123706/
https://www.ncbi.nlm.nih.gov/pubmed/21434995
http://dx.doi.org/10.1111/j.1464-5491.2011.03301.x

Ejemplares similares